Patents by Inventor David Lichtstein

David Lichtstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS
    Publication number: 20180369264
    Abstract: The present invention relates to pharmaceutical combinations for the treatment of cardiovascular diseases and disorders. More particularly, the invention relates to pharmaceutical combinations comprising a cardiac steroids CS and at least one PI3K/Akt/m TOR inhibitor. The compositions of the invention may particularly be used for reducing the CS dose administered to a subject suffering from a cardiovascular disease or disorders, thereby reducing the side effects associated with CS therapy. The invention further provides methods of treatment of such diseases and disorders using the pharmaceutical combinations.
    Type: Application
    Filed: December 20, 2016
    Publication date: December 27, 2018
    Inventors: David LICHTSTEIN, Nahum BUZAGLO
  • Use of Digitalis-Like Compounds in the Treatment of Affective Disorders
    Publication number: 20090209504
    Abstract: Use of digitalis-like compounds such as 19-norbufalin derivatives in the treatment of affective disorders such as anxiety, depression and bipolar disorders is disclosed.
    Type: Application
    Filed: March 22, 2007
    Publication date: August 20, 2009
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: David Lichtstein, Haim Rosen
  • 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
    Patent number: 7087590
    Abstract: A 19-norbufalin derivative compound of formula (I): wherein the R groups are as defined by the present specification. The compounds are Na+K?-ATPase inhibitors and can be used in the treatment of cardiac and/or vascular malfunction, renal malfunction, as digoxin antagonists, for treatment of CNS disorders and for the treatment of malignant and proliferative cell diseases.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: August 8, 2006
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: David Lichtstein, Joseph Deutsch
  • Digitalis-like compounds
    Patent number: 5874423
    Abstract: A human cataractous lens nuclei methanolic extract characterized in that it comprises substances having a molecular weight lower than 3000 daltons, inhibiting ATP hydrolysis by Na.sup.+,K.sup.+ -ATPase having affinity to the ouabain binding site on the enzyme and cross-reacting with an antibody directed against digoxin. Compounds of the general formula are disclosed: ##STR1## or of the general formula: ##STR2## in which R is hydrogen, an amino acid, a di- or tripeptide or a mono-, di- or trisaccharide. Pharmaceutical preparations and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: February 23, 1999
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: David Lichtstein, Joseph Deutsch, Irit Gati